We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+9.84%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$15.7B
AUM Growth
+$958M
Cap. Flow
-$459M
Cap. Flow %
-2.93%
Top 10 Hldgs %
22.96%
Holding
925
New
41
Increased
262
Reduced
364
Closed
130

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$97.5M
2
PYPL icon
PayPal
PYPL
+$66.8M
3
HOLX
Hologic
HOLX
+$44.4M
4
BNTX icon
BioNTech
BNTX
+$35M
5
TMO icon
Thermo Fisher Scientific
TMO
+$34.3M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$80.5M
2
XLRN
Acceleron Pharma
XLRN
+$79.5M
3
AAPL icon
Apple
AAPL
+$55.8M
4
ONC
BeOne Medicines Ltd
ONC
+$44.9M
5
VZ icon
Verizon
VZ
+$37.9M

Sector Composition

Rank Sector Weight
1 Healthcare 31.29%
2 Technology 26.69%
3 Financials 8.86%
4 Communication Services 7.82%
5 Consumer Discretionary 7.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NWL icon
551
Newell Brands
NWL
$2.15B
$1.82M 0.01%
83,487
+4,826
+6% +$109K
CAG icon
552
Conagra Brands
CAG
$7.41B
$1.82M 0.01%
53,338
+11,002
+26% +$360K
HRL icon
553
Hormel Foods
HRL
$14.3B
$1.82M 0.01%
37,313
+11,821
+46% +$518K
DVN icon
554
Devon Energy
DVN
$51B
$1.81M 0.01%
41,036
-18,510
-31% -$770K
IR icon
555
Ingersoll Rand
IR
$33.2B
$1.8M 0.01%
29,178
-3,880
-12% -$221K
VTR icon
556
Ventas
VTR
$47.7B
$1.8M 0.01%
35,203
+4,683
+15% +$245K
HBAN icon
557
Huntington Bancshares
HBAN
$34.4B
$1.79M 0.01%
115,962
-327,059
-74% -$5.15M
KKR icon
558
KKR & Co
KKR
$89.5B
$1.77M 0.01%
23,799
-50,834
-68% -$3.75M
CHD icon
559
Church & Dwight Co
CHD
$23.6B
$1.76M 0.01%
17,141
-6,419
-27% -$582K
UGI icon
560
UGI
UGI
$7.95B
$1.72M 0.01%
37,478
-121
-0.3% -$5.38K
ADM icon
561
Archer Daniels Midland
ADM
$39.6B
$1.72M 0.01%
25,418
-1,875
-7% -$121K
ALB icon
562
Albemarle
ALB
$13.4B
$1.69M 0.01%
7,245
-1,146
-14% -$284K
WTRG icon
563
Essential Utilities
WTRG
$11.6B
$1.69M 0.01%
31,521
-4,191
-12% -$203K
VFC icon
564
VF Corp
VFC
$5.93B
$1.69M 0.01%
23,089
-14,848
-39% -$1.08M
ARKK icon
565
ARK Innovation ETF
ARKK
$5.64B
$1.68M 0.01%
+17,760
New +$1.94M
GIL icon
566
Gildan
GIL
$9.5B
$1.67M 0.01%
39,320
-66,674
-63% -$2.64M
WY icon
567
Weyerhaeuser
WY
$17.6B
$1.66M 0.01%
40,263
-7,564
-16% -$287K
DRI icon
568
Darden Restaurants
DRI
$24.2B
$1.66M 0.01%
10,994
-709
-6% -$105K
BKR icon
569
Baker Hughes
BKR
$59.4B
$1.65M 0.01%
68,588
+7,152
+12% +$177K
ARKF icon
570
ARK Blockchain & Fintech Innovation ETF
ARKF
$735M
$1.65M 0.01%
+40,276
New +$1.94M
EXPD icon
571
Expeditors International
EXPD
$22.2B
$1.64M 0.01%
12,199
-45
-0.4% -$5.63K
TMHC
572
DELISTED
Taylor Morrison
TMHC
$1.62M 0.01%
+46,398
New +$1.45M
ROKU icon
573
Roku
ROKU
$21.4B
$1.62M 0.01%
7,089
+860
+14% +$232K
EG icon
574
Everest Group
EG
$15.8B
$1.61M 0.01%
5,891
PFG icon
575
Principal Financial Group
PFG
$24.6B
$1.61M 0.01%
22,256
-4,439
-17% -$310K

Similar funds

Candriam SCA's Q4 2021 Portfolio in Review

As of Q4 2021, Candriam SCA held 925 positions worth $15.7B, up 6.5% from $14.7B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Candriam SCA's Q4 2021 filing shows 41 new, 262 increased, 364 reduced and 130 closed positions. Its largest new stake was Couchbase: 858,038 shares worth $21.4M. The largest sale was Merck, an estimated $80.5M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q4 2021 buy was Couchbase: 858,038 shares worth $21.4M.
  • Candriam SCA added most to Eli Lilly in Q4 2021, an estimated $97.5M increase.
  • Candriam SCA's biggest Q4 2021 reduction was Merck, cutting an estimated $80.5M.
  • Candriam SCA fully exited Acceleron Pharma in Q4 2021, selling an estimated $79.5M.
  • Candriam SCA's ten largest holdings make up 23% of its $15.7B portfolio in Q4 2021.
  • Candriam SCA opened 41 new positions and closed 130 in Q4 2021.
  • Candriam SCA's portfolio value rose 6.5% quarter-over-quarter to $15.7B.

Based on Candriam SCA's 13F filing for Q4 2021, filed 10 Feb 2022.